The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

New insulin treatments for diabetes are hitting the market fast and furious these days. Biocon Biologics’ effort to move its insulin through the approval process in India, however, has landed the ...

BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...

Biocon Biologics is among the leading global suppliers of biosimilar insulins and has been expanding its portfolio ...

Biocon said its wholly owned subsidiary Biocon Pharma has received US FDA approval for its ANDA for Liraglutide Injection (gVictoza) 18 mg/3 mL prefilled pens used to treat Type 2 diabetes, following ...

Biocon said its arm, Biocon Pharma, has received approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Liraglutide injection (gVictoza), 18 mg ...

Earnings call Biocon reported 9% YoY revenue growth in Q3 FY26, with biosimilars and generics offsetting CRDMO softness. Core EBITDA rose 21% YoY to INR 1,221 crore with a 29% margin, driven by ...

Biocon Ltd. has announced that its first manufacturing facility in the US, located in Cranbury, New Jersey, has successfully undergone a critical Good Manufacturing Practices (GMP) inspection by the ...

Washington: The U.S. International Trade Commission (USITC) has received a complaint alleging that biosimilar versions of the cancer drug pertuzumab imported into the United States violate ...

HYDERABAD, Aug 11 (Reuters) - Indian biopharmaceutical company Biocon Ltd (BION.NS), opens new tab is planning to list its biosimilars business, a significant contributor to the company's total ...